Pain / Inflammation

Cannoflam™

Systemic anti-inflammatory support

Doctor use Clinician-led Pain / inflammation
Cannoflam™ product visual
Pain & Inflammation

Clinical positioning

Lower concentration cannabinoid-rich oil for inflammatory pain and mobility-support discussions.

Clinical use lens

Inflammation-first entry oil

A practical starting choice when pain is linked with stiffness, inflammatory tone or mobility limitation.

5 videos

Video brochure

Protocol mapping

Indication fit

Inflammatory pain Osteoarthritis Myofascial pain Mobility support
Why doctors reach for it

Clinical highlights

✦Inflammatory pain: lower-strength cannabinoid oil for titration
✓Mobility support: osteoarthritis, myofascial and soft-tissue discomfort contexts
→Carrier logic: coconut/MCT base supports absorption of lipophilic actives
How it is positioned to work

Mechanism map

1CB1/CB2 oriented endocannabinoid-system support
2Anti-inflammatory mediator balance and TRPV1 pain-signalling support
3MCT/coconut oil carrier improves solubilisation of lipophilic actives
Physician-directed dosing

Administration & dosing

X

Dose framework

X = body weight in kilograms
First dose
≤ X/2 mg
Grade-guided range
X–10X mg

First dose must never exceed X/2 mg total cannabinoids (equivalent to ≤0.5 mg/kg when X is body weight in kg). Further titration may move within X to 10X mg total cannabinoids only after tolerance and response review.

1–10

Indication grade

  • Grade 1–10: set by indication severity, pain/inflammation burden, ESR, CRP and symptom trajectory.
  • Adjust for age, frailty, secondary conditions, hepatic/renal risk, concurrent medicines and tolerance.
  • Use follow-up response to hold, increase, reduce or discontinue.
↗

Titration model

  • Incremental: gradual upward titration until response / tolerability.
  • Incremental–decremental: step up, then reduce to minimum effective maintenance.
  • Microdosing: very low divided exposure for sensitive, elderly or polypharmacy patients.
Rx

Administration

  • Oral / sublingual / with suitable carrier as per physician direction and product format.
  • Prefer consistent timing; document relation to food, sleep, pain peak, appetite or protocol goal.
  • Document dose, route, time, food/carrier, indication grade, ESR/CRP or relevant markers, adverse effects and follow-up plan.
  • Monitor sedation, dizziness, GI tolerance, cognition, drug interactions and functional response.

Full titration walkthrough: physician dosage guide.

In-clinic use

Doctor use notes & safety boundary

Doctor use notes

  • Start low and titrate by clinical context, tolerability and symptom severity.
  • Track response, co-medications, sedation, GI tolerance and follow-up outcome.
  • Document dose, timing, duration, indication and review plan.

Safety boundary

  • For registered medical practitioners only
  • Select dose by clinical context and tolerability
  • Monitor sedation, interactions and follow-up response
  • Not for direct patient promotion
2 actives

Formula / ingredients

IngredientBotanical / basePartQty
Vijaya leavesCannabis Sativa LinnLeaves10%
Coconut OilCocos Nucifera—90%
Clinic packs

Pack / MRP

PackStrengthMRP
10 ml (1 g)1000mg total cannabinoids≈ 5 mg/drop₹550
30 ml (3 g)3000mg total cannabinoids≈ 5 mg/drop₹1,299

Pack / MRP summary: 10 ml (1 g) ₹550 (1000mg) · 30 ml (3 g) ₹1,299 (3000mg)

4 source links

Audited research links

Audited reference fitClinical logicSource
CBD / cannabinoids
✓ Pain/inflammation checkedPMC full textScientific context
Cannabidiol as a Treatment for Arthritis and Joint Pain
Arthritis and joint pain research supportOpen ↗
CBD
✓ Pain/inflammation checkedPMC full textMechanistic rationale
CBD for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Pain pharmacology and CB2/TRPV1/5-HT1A mechanismsOpen ↗
Cannabis active compounds
✓ Pain/inflammation checkedPMC full textMechanistic rationale
Medical Cannabis Activity Against Inflammation: Active Compounds and Mechanisms
Anti-inflammatory active-compound mechanismsOpen ↗
MCT / lipid carrier
✓ Scientific fit checkedPMC full textScientific context
Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulations for Cannabidiol
CBD/MCT lipid-formulation and carrier-solubilisation contextOpen ↗
Educational use only. Doctor-facing scientific aid only. Research links are mapped for ingredient rationale, mechanism, clinical context and safety boundaries. This brochure does not replace diagnosis, standard-of-care treatment, regulatory prescribing rules or clinical monitoring. See our legal & medical disclaimer and editorial policy.
Same protocol

Related products